Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 01/09/2022

    Personalised antibiotic treatment strategies for tuberculosis patients

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
  • Press release - 01/08/2024

    Targeted therapy for cancer of unknown primary (Cup)

    Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
  • Press release - 13/10/2025

    Miniature 3D-printed objects inside the body

    Dr. Andrea Toulouse from the Institute of Applied Optics receives €1.8 million in funding from the Carl-Zeiss-Stiftung as part of the CZS Nexus program to establish a new junior research group. She conducts research in the field of micro-optics and fiber-based 3D printing. Her vision is to develop 3D printers that will one day be able to build biological tissue directly inside the body.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/miniature-3d-printed-objects-inside-body
  • NeuroQ project - 26/07/2023 Zu sehen ist eine Frau mit einer Exoskeletthand, die ein Plastikflasche hält.

    Quantum sensors for exoskeletons: can quantum physics beat paralysis?

    Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/quantum-sensors-exoskeletons-can-quantum-physics-beat-paralysis
  • Innovation in emergency medicine - 23/05/2024 Three men in white coats stand behind a mobile stand equipped with several small devices.

    CARL pushes back the boundaries of resuscitation therapy

    Few people survive a cardiac arrest; blood stops flowing to the brain and other vital organs and the resulting lack of oxygen causes extensive damage to the body. In response to this, researchers at the University Medical Centre Freiburg and Resuscitec GmbH have developed CARL, an innovative resuscitation system, which – in addition to the oxygen level – adjusts numerous blood parameters to individual patient requirements. This greatly improves…

    https://www.gesundheitsindustrie-bw.de/en/article/news/carl-pushes-back-boundaries-resuscitation-therapy
  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Help for tracheostomy patients - 23/10/2025 The image shows a plastic valve from the side.

    Biomimetic speaking valve: how a carnivorous plant makes speaking safer

    Nature is the best engineer, so they say, and it's always worth taking a closer look. An interdisciplinary group of researchers did just this and drew inspiration from an aquatic plant to develop a novel speaking valve for tracheostomy patients. At the University Medical Center Freiburg, Dr. Claudius Stahl and his team may have addressed a life-threatening issue that can arise in everyday clinical practice by creating a biomimetic valve with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/biomimetic-speaking-valve-how-carnivorous-plant-makes-speaking-safer
  • Press release - 10/08/2026

    Immune Cells in Bone Marrow Cancer: Limited Defense Readiness

    A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
  • Press release - 03/09/2024

    NMR Spectroscopy: A Faster Way to Determine the “Sense of Rotation” of Molecules

    Researchers of Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH developed a new method that allows, for the first time, to elucidate the chiral structure of molecules – the exact spatial arrangement of the atoms – by nuclear magnetic resonance (NMR) spectroscopy. This important step in the development of new drugs used to be a time-consuming process until now.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmr-spectroscopy-faster-way-determine-sense-rotation-molecules
  • Press release - 18/05/2026

    Unlocking the Lung’s Ability to Heal: NK Cell Immunotherapy offers New Hope for Fibrosis

    Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/unlocking-lungs-ability-heal-nk-cell-immunotherapy-offers-new-hope-fibrosis
  • microRNA as a prognostic biomarker - 13/01/2022 Screen of an ECG device showing the typical action potentials of the heart muscle.

    Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

    People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence
  • Press release - 17/06/2024

    DNA as building material for tiny machines and artificial cells

    Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dna-building-material-tiny-machines-and-artificial-cells
  • Dossier - 18/11/2013 The photo shows the lotus effect on new textiles developed at the ITV Denkendorf (Photo: BIOPRO)

    Innovative textiles made possible by biotechnology

    Biotechnology plays a part in many high-tech fabrics that have become an integral part of our everyday life. Whether it is products for the treatment of wounds, fabrics for marquees or for clothing, many materials have been developed or are produced using biotechnological techniques and processes. Many products marketed as “micro” or “nano” are inspired by nature.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/innovative-textiles-made-possible-by-biotechnology
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 17/10/2023

    BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform

    The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-und-yumab-verkuenden-partnerschaft-fuer-entwicklung-innovativer-safety-engager-r-plattform
  • Press release - 16/06/2025

    Novel laboratory models pave the way for targeted therapies for childhood sarcomas

    Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-laboratory-models-pave-way-targeted-therapies-childhood-sarcomas
  • Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 A comic-style illustration of a green sleeping sickness pathogen in blue tissue, with four surface proteins shown in grey, magnified as if under a magnifying glass, to which a green antibody binds.

    Reaching the unreachable: new approaches to challenging drug targets

    Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Article - 30/09/2019 Massenspektrometrie.jpg

    Do gut bacteria have something to do with autism?

    Autistic people have different gut microorganisms than non-autistic people. Researchers believe that a disturbed intestinal flora may play a role in developmental disorders of the brain such as autism. The emerging new field of metaproteomics could shed light onto the matter. A team led by Prof. Dr. Boris Macek from Tübingen has investigated the bacterial protein pool in the faeces of mice that display autistic behaviour.

    https://www.gesundheitsindustrie-bw.de/en/article/news/do-gut-bacteria-have-something-to-do-with-autism
  • Press release - 17/11/2022

    New target for Alzheimer's therapies found

    DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-target-alzheimers-therapies-found
  • Press release - 04/11/2022

    How do our brain cells age?

    The health of nerve cells is closely linked to the auxiliary cells that surround them, the so-called glial cells. It still remains largely unknown what role glial cells play in age-related diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-altern-die-zellen-unserem-gehirn
  • Press release - 15/02/2024

    Modelling the spread of diseases

    Computer scientists from the Cluster of Excellence Collective Behaviour developed a model, that explains how collective scenarios such as diseases may proceed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/modelling-spread-diseases
  • Press release - 08/01/2026

    Award for EMG electrode research

    How modern medical technology can prevent serious consequences of surgical procedures is demonstrated by a recent internationally recognized scientific publication. The study “Validation of conductive resin as electrode material in neuromonitoring with 3D-printed probes” under the leadership of Drs. Kiese and Bucher was awarded at the ICST Conference in Japan and highlights a medical topic that is crucial for the quality of life of many people.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-emg-electrode-research
  • Dossier - 09/03/2015 22868_de.jpg

    Advances in the study and treatment of liver diseases

    Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
  • Press release - 20/06/2022

    Protein changes in the liquor indicate inflammatory processes in the brain

    Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain

Page 21 / 25

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search